Factor Model (net +1.5)
Factor Model
net +1.5 3.9 / 10Q4 Beat Confirms 2026 Pipeline Confidence
Watch: Zanidatamab uptake and Modeyso/Zepzelca contribution by mid-year 2026 earnings. Any commercial outperformance above Street models could trigger consensus estimate raises and tighten the gap to the $220 target; underperformance opens the door to downside surprise.
Jazz Pharmaceuticals just locked in its 21st consecutive year of top-line growth, posting $1.2 billion in Q4 2025 revenue — a 10% YoY jump and a company record. The beat was modest (2.6% above consensus), but the real signal came in FY2026 guidance: $4.25B–$4.5B now aligns with consensus at the high end, replacing prior caution with explicit confidence that zanidatamab's pending gastroesophageal adenocarcinoma launch and ramps in Modeyso and Zepzelca will drive material growth. TD Cowen responded by raising its price target to $220 from $205 in January, betting the pipeline delivers. Legacy franchises Epidiolex (epilepsy) and Xywav (narcolepsy) remain strong anchors.
Guidance alignment matters because it removes the "show me" overhang that plagued prior frames. Jazz is no longer signaling pipeline as upside optionality — it's baking zanidatamab and newer oncology asset ramps into base guidance. If those launches hit or exceed internal assumptions, analyst estimate raises are likely and the $220 target becomes within reach. If adoption stumbles, the stock loses its upside cushion fast.
Our Trades
Full track record →Long Call · Wide Runner
2026-04-15
Long Call · Quick Draw
2026-04-14
Long Call · True Believer
2026-04-13
Evidence
Fundamentals & Data ▾
Recent transactions
Get alerted when JAZZ changes direction
We'll email you when our AI detects a shift — reversals, insider clusters, filing red flags.